Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Let The U.S. Drug-Coated Balloon Battle Begin

This article was originally published in The Gray Sheet

Executive Summary

Medtronic gained FDA approval for its drug-coated balloon for the peripheral artery, as expected, and it is now gunning to take share from first-to-market C.R. Bard with the help of impressive clinical data and a formidable Covidien peripheral vascular device sales force.

You may also be interested in...



Market Update: Growth And Opportunities In Peripheral Artery Disease

Drug-coated balloon (DCBs) catheters have become the latest weapon in the fight against peripheral artery disease in the US, although they have been in use in Europe for some time. While the number of procedures employing DCBs is still dwarfed by conventional angioplasty procedures, they are expected to grow at a much faster rate, fueling a market projected to reach $1 billion by 2020; meanwhile other procedures such as mechanical atherectomy are also expected to show significant growth.

New Product Briefs

Product announcements from LivaNova, Smith & Nephew, Medtronic, Boston Scientific and Animas.

Drug-Coated Balloons Net Medicare Inpatient Bonus Payments

The positive hospital inpatient reimbursement decision for recently launched Medtronic and CR Bard peripheral artery devices follows prior positive policy rulings in the outpatient setting. Meanwhile, CMS rejected Boston Scientific's new-technology add-on application for the Watchman stroke device, but the agency did establish a pricier payment category for the new procedure.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

MT033898

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel